LitAlert ~~ GeneLit.com

    • RNA sequencing and bioinformatics analysis revealed PACSIN3 as a potential novel biomarker for platinum resistance in epithelial ovarian cancer.
    • Han GH, Shim JE, Yun H, Kim J, Kim JH, Cho H.
    • J Gene Med. 2022 Sep 28:e3452. doi: 10.1002/jgm.3452. Epub ahead of print.
    • Detection of Breast Cancer Lump and BRCA1/2 Genetic Mutation under Deep Learning.
    • Miao Y, Tang S.
    • Comput Intell Neurosci. 2022 Sep 19;2022:9591781. doi: 10.1155/2022/9591781.
    • From seaside to bedside: Current evidence and future perspectives in the treatment of breast cancer using marine compounds.
    • De Sanctis R, Jacobs F, Benvenuti C, Gaudio M, Franceschini R, Tancredi R, Pedrazzoli P, Santoro A, Zambelli A.
    • Front Pharmacol. 2022 Sep 8;13:909566. doi: 10.3389/fphar.2022.909566.
    • Using Patient-Derived Xenograft (PDX) Models as a ‘Black Box’ to Identify More Applicable Patients for ADP-Ribose Polymerase Inhibitor (PARPi) Treatment in Ovarian Cancer: Searching for Novel Molecular and Clinical Biomarkers and Performing a Prospective Preclinical Trial.
    • Chen J, Li Y, Wang H, Li T, Gu Y, Wang W, Shan Y, Yin J, Wang Y, Qin M, Li S, Pan L, Peng S, Jin Y.
    • Cancers (Basel). 2022 Sep 24;14(19):4649. doi: 10.3390/cancers14194649.
  • LitAlert ~~ GeneLit.com

    • What’s beyond BRCA Mutational Status in High Grade Serous Ovarian Cancer? The Impact of Hormone Receptor Expression in a Large BRCA-Profiled Ovarian Cancer Patient Series: A Retrospective Cohort Study.
    • Perrone E, Tudisco R, Pafundi PC, Guido D, Ciucci A, Martinelli E, Zannoni GF, Piermattei A, Spadola S, Ferrante G, Marchetti C, Scambia G, Fagotti A, Gallo D.
    • Cancers (Basel). 2022 Sep 22;14(19):4588. doi: 10.3390/cancers14194588.
    • RNA-based classification of homologous recombination deficiency in racially-diverse patients with breast cancer.
    • Walens A, Van Alsten SC, Olsson LT, Smith MA, Lockhart A, Gao X, Hamilton AM, Kirk EL, Love MI, Gupta GP, Perou CM, Vaziri C, Hoadley KA, Troester MA.
    • Cancer Epidemiol Biomarkers Prev. 2022 Sep 21:EPI-22-0590. doi: 10.1158/1055-9965.EPI-22-0590. Epub ahead of print.
    • Niraparib-induced STAT3 inhibition increases its antitumor effects.
    • Yu HE, Rodriguez-Rodriguez L, Zhao Q, Kohut A, Li YJ, Martincuks A, Austria T, Zhang C, Santiago NL, Borrero RM, Phan XT, Melstrom L.
    • Front Oncol. 2022 Sep 21;12:966492. doi: 10.3389/fonc.2022.966492.
    • DNA-PKcs promotes fork reversal and chemoresistance.
    • Dibitetto D, Marshall S, Sanchi A, Liptay M, Badar J, Lopes M, Rottenberg S, Smolka MB.
    • Mol Cell. 2022 Sep 10:S1097-2765(22)00848-6. doi: 10.1016/j.molcel.2022.08.028. Epub ahead of print.
  • LitAlert ~~ GeneLit.com

    • Merck KGaA, Nerviano Enter License Agreement for PARP1 Inhibitor NMS-293.
    • [No author given]
    • Precision Oncology News. 2022 Sep 21.

    Identifier: NCT04182516: Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors. (ClinicalTrials.gov)

    • Identification of RP-6685, an Orally Bioavailable Compound that Inhibits the DNA Polymerase Activity of Pol?.
    • Bubenik M, Mader P, Mochirian P, Vallée F, Clark J, Truchon JF, Perryman AL, Pau V, Kurinov I, Zahn KE, Leclaire ME, Papp R, Mathieu MC, Hamel M, Duffy NM, Godbout C, Casas-Selves M, Falgueyret JP, Baruah PS, Nicolas O, Stocco R, Poirier H, Martino G, Fortin AB, Roulston A, Chefson A, Dorich S, St-Onge M, Patel P, Pellerin C, Ciblat S, Pinter T, Barabé F, El Bakkouri M, Parikh P, Gervais C, Sfeir A, Mamane Y, Morris SJ, Black WC, Sicheri F, Gallant M.
    • J Med Chem. 2022 Sep 20. doi: 10.1021/acs.jmedchem.2c00998. Epub ahead of print.
  • LitAlert ~~ GeneLit.com

    • TSG101 associates with PARP1 and is essential for PARylation and DNA damage-induced NF-?B activation.
    • Tufan AB, Lazarow K, Kolesnichenko M, Sporbert A, von Kries JP, Scheidereit C.
    • EMBO J. 2022 Sep 20:e110372. doi: 10.15252/embj.2021110372. Epub ahead of print.
    • KP372-1-Induced AKT Hyperactivation Blocks DNA Repair to Synergize With PARP Inhibitor Rucaparib via Inhibiting FOXO3a/GADD45a Pathway.
    • Jiang L, Liu Y, Su X, Wang J, Zhao Y, Tumbath S, Kilgore JA, Williams NS, Chen Y, Wang X, Mendonca MS, Lu T, Fu YX, Huang X.
    • Front Oncol. 2022 Sep 20;12:976292. doi: 10.3389/fonc.2022.976292.
  • LitAlert ~~ GeneLit.com

    • Sequential Targeting of PLK1 and PARP1 Reverses the Resistance to PARP Inhibitors and Enhances Platin-Based Chemotherapy in BRCA-Deficient High-Grade Serous Ovarian Cancer with KRAS Amplification.
    • Gasimli K, Raab M, Rad MT, Kurunci-Csacsko E, Becker S, Strebhardt K, Sanhaji M.
    • Int J Mol Sci. 2022 Sep 17;23(18):10892. doi: 10.3390/ijms231810892.
    • Prostate cancer transcriptomic regulation by the interplay of germline risk alleles, somatic mutations and 3D-genomic architecture.
    • Yuan J, Houlahan KE, Ramanand SG, Lee S, Baek G, Yang Y, Chen Y, Strand DW, Zhang MQ, Boutros PC, Mani RS.
    • Cancer Discov. 2022 Sep 15:CD-22-0027. doi: 10.1158/2159-8290.CD-22-0027. Epub ahead of print.
    • Pan-cancer analysis of co-occurring mutations in RAD52 and the BRCA1-BRCA2-PALB2 axis in human cancers.
    • Hamid AB, Frank LE, Bouley RA, Petreaca RC.
    • PLoS One. 2022 Sep 15;17(9):e0273736. doi: 10.1371/journal.pone.0273736.
    • B7-H3 as a Therapeutic Target in Advanced Prostate Cancer.
    • Guo C, Figueiredo I, Gurel B, Neeb A, Seed G, Crespo M, Carreira S, Rekowski J, Buroni L, Welti J, Bogdan D, Gallagher L, Sharp A, Fenor de la Maza MD, Rescigno P, Westaby D, Chandran K, Riisnaes R, Ferreira A, Miranda S, Calì B, Alimonti A, Bressan S, Nguyen AHT, Shen MM, Hawley JE, Obradovic A, Drake CG, Bertan C, Baker C, Tunariu N, Yuan W, de Bono JS.
    • Eur Urol. 2022 Sep 13:S0302-2838(22)02633-1. doi: 10.1016/j.eururo.2022.09.004. Epub ahead of print.
  • LitAlert ~~ GeneLit.com

    • Enhanced Antitumoral Activity of Encapsulated BET Inhibitors When Combined with PARP Inhibitors for the Treatment of Triple-Negative Breast and Ovarian Cancers.
    • Juan A, de Mar Noblejas-López M, Bravo I, Arenas-Moreira M, Blasco-Navarro C, Clemente-Casares P, Lara-Sánchez A, Pandiella A, Alonso-Moreno C, Ocaña A.
    • Cancers (Basel). 2022 Sep 15;14(18):4474. doi: 10.3390/cancers14184474.
    • PARP targeted Auger emitter therapy with [125I]PARPi-01 for triple-negative breast cancer.
    • Ambur Sankaranarayana R, Florea A, Allekotte S, Vogg ATJ, Maurer J, Schäfer L, Bolm C, Terhorst S, Classen A, Bauwens M, Morgenroth A, Mottaghy FM.
    • EJNMMI Res. 2022 Sep 14;12(1):60. doi: 10.1186/s13550-022-00932-9.
  • LitAlert ~~ GeneLit.com

    • Imaging Agent May Have Potential as Noninvasive Test to Predict PARP Inhibitor Response.
    • Hopkins C.
    • Precision Oncology News. 2022 Sep 13.
    • Error-prone repair of stalled replication forks drives mutagenesis and loss of heterozygosity in haploinsufficient BRCA1 cells.
    • Deshpande M, Paniza T, Jalloul N, Nanjangud G, Twarowski J, Koren A, Zaninovic N, Zhan Q, Chadalavada K, Malkova A, Khiabanian H, Madireddy A, Rosenwaks Z, Gerhardt J.
    • Mol Cell. 2022 Sep 7 [2022 Sep 12]:S1097-2765(22)00806-1. doi: 10.1016/j.molcel.2022.08.017. Epub ahead of print.
    • Combination of ligand and structure based virtual screening approaches for the discovery of potential PARP1 inhibitors.
    • Al-Sanea MM, Chilingaryan G, Abelyan N, Mamikonyan M, Gasparyan H, Hovhannisyan S, Hamdi A, Ali AR, Selim S, Mohamed AAB.
    • PLoS One. 2022 Sep 12;17(9):e0272065. doi: 10.1371/journal.pone.0272065.